<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01654445</url>
  </required_header>
  <id_info>
    <org_study_id>Version 2.2, Aug 28,2013</org_study_id>
    <nct_id>NCT01654445</nct_id>
  </id_info>
  <brief_title>TNK-tPA Evaluation for Minor Ischemic Stroke With Proven Occlusion</brief_title>
  <acronym>TEMPO-1</acronym>
  <official_title>A Phase 2, Prospective, Two Cohort, Dose-escalation, Safety and Feasibility Study of Thrombolysis for Minor Ischemic Stroke With Proven Acute Symptomatic Occlusion Using TNK-tPA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vancouver General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hopital Charles Lemoyne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universit√© de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vancouver Island Health Authority</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CHU de Quebec-Universite Laval</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Calgary</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will enroll patients that have been diagnosed with a transient ischemic attack&#xD;
      (TIA) or minor stroke that has occurred within the past 12 hours. Anyone diagnosed with a&#xD;
      minor stroke faces the possibility of long-term disability and even death, regardless of&#xD;
      treatment. Stroke symptoms such as weakness, difficulty speaking and paralysis may improve or&#xD;
      worsen over the hours or days immediately following a stroke. The purpose of this research&#xD;
      trial is to study the effects of a clot-dissolving drug, tenecteplase (TNK-tPA), as a&#xD;
      treatment for patients who arrive within twelve hours from stroke onset. This study is&#xD;
      attempting to see if TNK-tPA given through a vein in the arm (intravenous) to patients is a&#xD;
      safe treatment for stroke patients. Neither the safety nor the effectiveness of this&#xD;
      treatment has been proven yet.&#xD;
&#xD;
      This trial will be conducted at several site in Canada.&#xD;
&#xD;
      Dr Michael Hill and Dr. Shelagh Coutts are the Principal Investigators of this trial,&#xD;
      coordinated at the University of Calgary, Foothills Medical Centre.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of TEMPO-1 is to demonstrate the safety and feasibility of using&#xD;
      TNK-tPA (tenecteplase), a thrombolytic agent that is relatively novel to the treatment&#xD;
      ischemic stroke but well-established in the treatment of myocardial infarction, to treat&#xD;
      minor ischemic stroke patients with proven acute symptomatic occlusions. Up to 80% of&#xD;
      ischemic stroke is minor and initially non-disabling. These patients present with a transient&#xD;
      ischemic attack (TIA) or minor stroke.An overwhelming majority are not treated with&#xD;
      thrombolysis as they are considered &quot;too good to treat&quot; by most physicians.&#xD;
&#xD;
      TEMPO-1 will enroll patients within a 12 hour time window with a NIHSS score of &lt;6 and an&#xD;
      ASPECTS &gt;5. Patients must have an intracranial occlusion on CTA. Study drug must be&#xD;
      administered within 90 minutes from the first slice of CTA. This is an open- label,&#xD;
      multi-centre trial, dose- escalated trial. A total of 50 patients will be enrolled, 25 per&#xD;
      tier. There will two dose tiers at 0.1 mg/kg and 0.25 mg/kg. Advancement to the second&#xD;
      dose-tier will be dependent upon safe completion of the 1st dose tier and the approval of the&#xD;
      DSMB.&#xD;
&#xD;
      Patients will undergo a study CT angiogram of the intracranial circulation between 4-8 hours&#xD;
      after treatment to determine the biological effect of the drug - whether the occluded artery&#xD;
      has recanalized or not. Patients will be assessed at 24 and 48 hours, and at Days 5, 30, and&#xD;
      90.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Serious Bleeding Events</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>The primary safety outcome will be the rate of expected serious adverse events associated with study drug. This will be defined as the number patients with at least one SAE divided by the number of patients enrolled by dose-tier. Thus, the unit of analysis will be the patient and not the SAE.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With NIHSS 0 and mRS 0 and Barthel Index &gt; 90</measure>
    <time_frame>90 days</time_frame>
    <description>Complete neurological and functional recovery at 90 days defined as: NIHSS 0 and mRS 0 iii)Complete neurological and functional recovery at 90 days defined as: a. NIHSS 0-1 and mRS 0-1 and Barthel Index &gt; 90&#xD;
NIHSS = National Institutes of Health Stroke Scale. This integer scale ranges 0-42 and is a quantitative measure of the neurological examination.&#xD;
mRS = modified Rankin Scale. This integer scale ranges from 0-6 and is a criterion-based quantitative measure of functional neurological disability.&#xD;
BI = Barthel Index. This scale range from 0-100 (in increments of 5 points) and is a summative categorical score measuring activities of daily living.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Patients With Recanalization 4-8 Hours Post-treatment</measure>
    <time_frame>4-8 hours</time_frame>
    <description>Recanalization defined on follow-up 4-8 hour CTA as a modified arterial occlusive lesion (mAOL) score 0-1.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>TNK-tPA Tenecteplase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is an open-label trial, all patients will receive tenecteplase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenecteplase</intervention_name>
    <description>Tenecteplase will be given to the patient as an intravenous bolus over 1- 2 minutes within 90 minutes of the first slice of the CTA. This is an open-label trial, all patients will receive tenecteplase, either tier 1 or tier 2 dosage.</description>
    <arm_group_label>TNK-tPA Tenecteplase</arm_group_label>
    <other_name>TNK-tPA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Acute ischemic stroke in an adult patient (18 years of age or older)&#xD;
&#xD;
          2. Onset (last-seen-well) time to treatment time &lt; 12 hours.&#xD;
&#xD;
          3. Minor stroke defined as a baseline NIHSS &lt; 6 at the time of randomization. Patients&#xD;
             must have a demonstrable neurological deficit on physical neurological examination.&#xD;
&#xD;
          4. Any acute intracranial occlusion (MCA, ACA, PCA, VB territories) defined by&#xD;
             non-invasive acute imaging (CT angiography) that is neurologically relevant to the&#xD;
             presenting symptoms and signs. An acute occlusion is defined as TICI 0 or TICI 1 flow.&#xD;
&#xD;
          5. Pre-stroke independent functional status in activities of daily living with pre-stroke&#xD;
             estimated modified Barthel Index of 90 or greater AND premorbid mRS 0 or 1.&#xD;
&#xD;
          6. Informed consent from the patient or surrogate.&#xD;
&#xD;
          7. Patients can be treated within 90 minutes of the CT/CTA being completed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hyperdensity on NCCT consistent with any intracranial hemorrhage. Any clinical&#xD;
             suspicion of any intracranial hemorrhage even in the absence of visible blood on&#xD;
             baseline brain imaging.&#xD;
&#xD;
          2. Large acute stroke &gt;1/3 MCA territory or ASPECTS&lt;5 visible on baseline CT scan.&#xD;
&#xD;
          3. Core of established infarction. No area of grey matter hypodensity at a similar or&#xD;
             lesser density to white matter or in the judgment of the enrolling neurologist is&#xD;
             consistent with a subacute ischemic stroke &gt; 12 hours of age.&#xD;
&#xD;
          4. Clinical history, past imaging and clinical judgment suggest that the intracranial&#xD;
             occlusion is chronic.&#xD;
&#xD;
          5. Patient is a candidate for and should receive standard of care IV tPA.&#xD;
&#xD;
          6. Stroke occurring as an in-patient. An in-patient is a person who has been officially&#xD;
             admitted to the hospital to a ward bed. A patient in the ED who has not been formally&#xD;
             admitted is still considered to be an outpatient.&#xD;
&#xD;
          7. Patient has a severe or fatal or disabling illness that will prevent improvement or&#xD;
             follow-up or such that the treatment would not likely benefit the patient.&#xD;
&#xD;
          8. Patient cannot complete follow-up due to co-morbid non-fatal illness or is visiting&#xD;
             the host sites city and cannot return for follow-up.&#xD;
&#xD;
          9. Pregnancy.&#xD;
&#xD;
         10. Patient is actively taking dual antiplatelet medication (aspirin &amp; clopidogrel) in the&#xD;
             last 48 hours.&#xD;
&#xD;
         11. International normalized ratio &gt; 1.4&#xD;
&#xD;
         12. Standard thrombolysis exclusions (Taken from Canadian guidelines1)&#xD;
&#xD;
        NOTES: NIHSS = National Institutes of Health Stroke Scale ACA = anterior cerebral artery&#xD;
        MCA = middle cerebral artery ICA = internal cerebral artery PCA = posterior cerebral artery&#xD;
        VB = vertebrobasilar TICI = thrombolysis in cerebral ischemic scale CT = computed&#xD;
        tomography NCCT = non-contrast CT CTA = CT angiography ASPECTS = Alberta Stroke Program&#xD;
        Early CT Score IV = intravenous tPA = tissue plasminogen activator ED = Emergency&#xD;
        Department&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael D Hill, MD,MSc FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shelagh B Coutts, MD,FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.ucalgary.ca/dcns/research/clinical_trials/TEMPO-1</url>
    <description>TEMPO-1 site</description>
  </link>
  <results_reference>
    <citation>Coutts SB, Dubuc V, Mandzia J, Kenney C, Demchuk AM, Smith EE, Subramaniam S, Goyal M, Patil S, Menon BK, Barber PA, Dowlatshahi D, Field T, Asdaghi N, Camden MC, Hill MD; TEMPO-1 Investigators. Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion. Stroke. 2015 Mar;46(3):769-74. doi: 10.1161/STROKEAHA.114.008504. Epub 2015 Feb 12.</citation>
    <PMID>25677596</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 25, 2012</study_first_submitted>
  <study_first_submitted_qc>July 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2012</study_first_posted>
  <results_first_submitted>April 6, 2015</results_first_submitted>
  <results_first_submitted_qc>November 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 25, 2020</results_first_posted>
  <last_update_submitted>November 23, 2020</last_update_submitted>
  <last_update_submitted_qc>November 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Calgary</investigator_affiliation>
    <investigator_full_name>Dr. Michael Hill</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>Minor stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenecteplase</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 6, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT01654445/SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from July 2012 through July 2014</recruitment_details>
      <pre_assignment_details>All patients were treated with study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tenecteplase 0.1 mg/kg</title>
          <description>25 patients treated with 0.1 mg/kg intravenous tenecteplase</description>
        </group>
        <group group_id="P2">
          <title>Tenecteplase 0.25 mg/kg</title>
          <description>25 patients treated with 0.25 mg/kg intravenous tenecteplase</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Adults (age &gt; 18) without an upper age limit, men and women with an acute ischemic stroke, less than 12 hours from symptom onset, who had a proven intracranial occlusion shown on CT angiography.</population>
      <group_list>
        <group group_id="B1">
          <title>Tenecteplase 0.1 mg/kg</title>
          <description>25 patients treated with 0.1 mg/kg intravenous tenecteplase</description>
        </group>
        <group group_id="B2">
          <title>Tenecteplase 0.25 mg/kg</title>
          <description>25 patients treated with 0.25 mg/kg intravenous tenecteplase</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72" lower_limit="60" upper_limit="82"/>
                    <measurement group_id="B2" value="71" lower_limit="61" upper_limit="81"/>
                    <measurement group_id="B3" value="71" lower_limit="60" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Serious Bleeding Events</title>
        <description>The primary safety outcome will be the rate of expected serious adverse events associated with study drug. This will be defined as the number patients with at least one SAE divided by the number of patients enrolled by dose-tier. Thus, the unit of analysis will be the patient and not the SAE.</description>
        <time_frame>Up to 12 weeks</time_frame>
        <population>All participants</population>
        <group_list>
          <group group_id="O1">
            <title>Tenecteplase 0.1 mg/kg</title>
            <description>25 patients treated with 0.1 mg/kg intravenous tenecteplase</description>
          </group>
          <group group_id="O2">
            <title>Tenecteplase 0.25 mg/kg</title>
            <description>25 patients treated with 0.25 mg/kg intravenous tenecteplase</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Serious Bleeding Events</title>
          <description>The primary safety outcome will be the rate of expected serious adverse events associated with study drug. This will be defined as the number patients with at least one SAE divided by the number of patients enrolled by dose-tier. Thus, the unit of analysis will be the patient and not the SAE.</description>
          <population>All participants</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With NIHSS 0 and mRS 0 and Barthel Index &gt; 90</title>
        <description>Complete neurological and functional recovery at 90 days defined as: NIHSS 0 and mRS 0 iii)Complete neurological and functional recovery at 90 days defined as: a. NIHSS 0-1 and mRS 0-1 and Barthel Index &gt; 90&#xD;
NIHSS = National Institutes of Health Stroke Scale. This integer scale ranges 0-42 and is a quantitative measure of the neurological examination.&#xD;
mRS = modified Rankin Scale. This integer scale ranges from 0-6 and is a criterion-based quantitative measure of functional neurological disability.&#xD;
BI = Barthel Index. This scale range from 0-100 (in increments of 5 points) and is a summative categorical score measuring activities of daily living.</description>
        <time_frame>90 days</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Tenecteplase 0.1 mg/kg</title>
            <description>25 patients treated with 0.1 mg/kg intravenous tenecteplase</description>
          </group>
          <group group_id="O2">
            <title>Tenecteplase 0.25 mg/kg</title>
            <description>25 patients treated with 0.25 mg/kg intravenous tenecteplase</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With NIHSS 0 and mRS 0 and Barthel Index &gt; 90</title>
          <description>Complete neurological and functional recovery at 90 days defined as: NIHSS 0 and mRS 0 iii)Complete neurological and functional recovery at 90 days defined as: a. NIHSS 0-1 and mRS 0-1 and Barthel Index &gt; 90&#xD;
NIHSS = National Institutes of Health Stroke Scale. This integer scale ranges 0-42 and is a quantitative measure of the neurological examination.&#xD;
mRS = modified Rankin Scale. This integer scale ranges from 0-6 and is a criterion-based quantitative measure of functional neurological disability.&#xD;
BI = Barthel Index. This scale range from 0-100 (in increments of 5 points) and is a summative categorical score measuring activities of daily living.</description>
          <population>All enrolled participants</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NIHSS = 0 at 90d</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mRS = 0 at 90d</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Barthel Index &gt; 90 at 90d</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients With Recanalization 4-8 Hours Post-treatment</title>
        <description>Recanalization defined on follow-up 4-8 hour CTA as a modified arterial occlusive lesion (mAOL) score 0-1.</description>
        <time_frame>4-8 hours</time_frame>
        <population>2 patients in each tier had missing data on this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Tenecteplase 0.1 mg/kg</title>
            <description>25 patients treated with 0.1 mg/kg intravenous tenecteplase</description>
          </group>
          <group group_id="O2">
            <title>Tenecteplase 0.25 mg/kg</title>
            <description>25 patients treated with 0.25 mg/kg intravenous tenecteplase</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Recanalization 4-8 Hours Post-treatment</title>
          <description>Recanalization defined on follow-up 4-8 hour CTA as a modified arterial occlusive lesion (mAOL) score 0-1.</description>
          <population>2 patients in each tier had missing data on this outcome.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>90 days from the date of enrolment</time_frame>
      <desc>Symptomatic intracranial hemorrhage</desc>
      <group_list>
        <group group_id="E1">
          <title>Tenecteplase 0.1 mg/kg</title>
          <description>25 patients treated with 0.1 mg/kg intravenous tenecteplase</description>
        </group>
        <group group_id="E2">
          <title>Tenecteplase 0.25 mg/kg</title>
          <description>25 patients treated with 0.25 mg/kg intravenous tenecteplase</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>SICH</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>symptomatic intracerebral hemorrhage</sub_title>
                <description>New posterior L temporal ICH (~15cc volume) with some associated sulcal SAH, contralateral to her stroke. New neurological deficits of aphasia. NIHSS remained at 4, but with different symptoms. Radiological classification rPH.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>asICH</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title vocab="atrial fibrillation">Atrial fibrillation</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Asymptomatic intracerebral hemorrhage</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title vocab="headache">Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title vocab="UTI">Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="bruising/hematoma">Bruising/hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title vocab="CEA">Carotid revascluarization (CEA or CAS)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>TEMPO-1 was a phase 2 study with a limited sample size. The program was designed to assess feasibility and safety and not efficacy. A further larger phase 3 study is planned.&#xD;
Only selected adverse events are presented here. All SAEs are reported.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Shelagh B Coutts and Michael D Hill</name_or_title>
      <organization>University of Calgary, Department of Clinical Neurosciences</organization>
      <phone>4039448065</phone>
      <email>michael.hill@ucalgary.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

